Meeting
2019 Gastrointestinal Cancers Symposium
Evaluation of disease-specific and functional symptom items on carcinoid tumor patients treated with telotristat ethyl.
Authors
Stacie Hudgens
Clinical Outcomes Solutions, Tucson, AZ
Stacie Hudgens , Pablo Lapuerta , Lysbeth Floden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01677910
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 427)
DOI
10.1200/JCO.2019.37.4_suppl.427
Abstract #
427
Poster Bd #
N7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.
First Author: William D. Tap
Poster
2018 Gastrointestinal Cancers Symposium
Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analysis of the phase III telecast study.
First Author: Joseph Dillon
Poster
2017 ASCO Annual Meeting
Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia.
First Author: Jalaja Potluri
Poster
2014 ASCO Annual Meeting
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.
First Author: Paolo Ghia